Atossa Genetics (NASDAQ:ATOS) Share Price Passes Above 200 Day Moving Average - What's Next?

Key Points

• Atossa Genetics' stock has surpassed its 200-day moving average of $0.79, trading recently at $0.75 with a volume of 746,758 shares.
• Analysts have raised their price targets, with Ascendiant Capital rating it a "buy" and increasing the target from $7.25 to $7.50, while Craig Hallum set a target of $4.00 after rating it as "strong-buy."
• Following their latest earnings report, Atossa Genetics missed analyst expectations with an EPS of ($0.07), leading to a consensus forecast of -0.22 EPS for the year.

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.79 and traded as high as $0.79. Atossa Genetics shares last traded at $0.75, with a volume of 746,758 shares changing hands.

Analysts Set New Price Targets

ATOS has been the subject of a number of research reports. Ascendiant Capital Markets increased their price target on Atossa Genetics from $7.25 to $7.50 and gave the company a "buy" rating in a research note on Friday, June 6th. Craig Hallum raised Atossa Genetics to a "strong-buy" rating and set a $4.00 price target for the company in a research note on Thursday, June 5th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $6.17.

Atossa Genetics Price Performance

The stock has a fifty day moving average price of $0.84 and a 200-day moving average price of $0.79. The company has a market cap of $96.88 million, a PE ratio of -3.26 and a beta of 0.92.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). On average, equities analysts anticipate that Atossa Genetics Inc. will post -0.22 earnings per share for the current year.

Institutional Trading of Atossa Genetics

A number of hedge funds have recently modified their holdings of the business. Hudson Bay Capital Management LP purchased a new stake in shares of Atossa Genetics in the second quarter valued at $26,000. Bank of America Corp DE raised its holdings in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company's stock worth $83,000 after acquiring an additional 35,629 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Atossa Genetics during the second quarter worth $2,468,000. Jane Street Group LLC purchased a new stake in shares of Atossa Genetics during the second quarter worth $381,000. Finally, Qube Research & Technologies Ltd raised its holdings in shares of Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company's stock worth $346,000 after acquiring an additional 325,340 shares in the last quarter. Hedge funds and other institutional investors own 12.74% of the company's stock.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.